AstraZeneca, the British pharmaceuticals giant, announced US$275 million in revenue from its Covid vaccine in the first three months of the year on Friday.
It’s the first time the company has revealed sales figures for one of the world’s most common vaccines.
The Covid-19 vaccine, developed by AstraZeneca in collaboration with the University of Oxford, has proven to be effective in the United Kingdom.
However, public confidence in the vaccine has been shaken by concerns about ties to extremely rare blood clots, and the firm is fighting the EU over distribution delays.
In Q1, Net Profit Doubled
Quoting AT, the company revealed the information in an earnings statement that showed net profit more than doubled in the first quarter to $1.56 billion, up from $780 million a year ago.
Revenue increased by 15% –or 11% at constant exchange rates – to $7.32 billion in the reporting period.
Excluding the contribution from the Covid jab, revenues rose by 11% – or 7.0% at constant rates – to $7.045 billion.
AstraZeneca added Thursday that its quarterly performance was boosted by strong sales of new cancer drugs.
Read now: US Stops Production of AstraZeneca Vaccine After Factory Incident
